来曲唑-话题@MedSci

#来曲唑#

31篇内容 | 2428人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1340417, encodeId=bdd2134041e41, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果, objectType=article, longId=195894, objectId=347c195894a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=347c195894a4, replyNumber=0, likeNumber=98, createdTime=2020-06-16, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=347c195894a4, moduleTitle=Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=347c195894a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340416, encodeId=db0e134041669, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=恒瑞医药来曲唑片通过仿制药一致性评价, objectType=article, longId=182568, objectId=721418256882, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=721418256882, replyNumber=0, likeNumber=105, createdTime=2019-11-09, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=721418256882, moduleTitle=恒瑞医药来曲唑片通过仿制药一致性评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=721418256882)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340415, encodeId=701e13404155f, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=仑伐替尼联合来曲唑在绝经后HR+局部晚期/转移性乳腺癌中的探索, objectType=article, longId=166861, objectId=f28a1668612c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f28a1668612c, replyNumber=0, likeNumber=106, createdTime=2019-05-28, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f28a1668612c, moduleTitle=仑伐替尼联合来曲唑在绝经后HR+局部晚期/转移性乳腺癌中的探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f28a1668612c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340414, encodeId=6bfe13404141f, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=Lancet oncol：来曲唑维持治疗不能延长乳腺癌患者化疗后的无病存活期, objectType=article, longId=155382, objectId=c41215538266, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c41215538266, replyNumber=0, likeNumber=77, createdTime=2018-12-10, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c41215538266, moduleTitle=Lancet oncol：来曲唑维持治疗不能延长乳腺癌患者化疗后的无病存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c41215538266)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340413, encodeId=408713404130c, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=J Clin Oncol：来曲唑治疗延长至10年乳腺癌症的患者生活质量有无影响？, objectType=article, longId=133886, objectId=0b421338867e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b421338867e, replyNumber=0, likeNumber=80, createdTime=2018-04-01, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b421338867e, moduleTitle=J Clin Oncol：来曲唑治疗延长至10年乳腺癌症的患者生活质量有无影响？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b421338867e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340412, encodeId=335413404129c, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=重复 Lancet Oncol：绝经后乳腺癌患者：延长来曲唑的间歇使用能否改善无疾病存活率？, objectType=article, longId=124805, objectId=e7361248056c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7361248056c, replyNumber=0, likeNumber=86, createdTime=2017-12-28, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7361248056c, moduleTitle=重复 Lancet Oncol：绝经后乳腺癌患者：延长来曲唑的间歇使用能否改善无疾病存活率？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7361248056c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340411, encodeId=47121340411ec, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=Lancet Oncol：来曲唑治疗方案对早期乳腺癌患者无进展生存期的影响, objectType=article, longId=120823, objectId=c0e612082300, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0e612082300, replyNumber=0, likeNumber=83, createdTime=2017-11-22, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0e612082300, moduleTitle=Lancet Oncol：来曲唑治疗方案对早期乳腺癌患者无进展生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0e612082300)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340410, encodeId=535b1340410e7, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=Hum Reprod：来曲唑比枸橼酸氯米芬治疗低生育力PCOS女性效果更好, objectType=article, longId=112299, objectId=9b5e11229961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b5e11229961, replyNumber=0, likeNumber=78, createdTime=2017-09-09, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b5e11229961, moduleTitle=Hum Reprod：来曲唑比枸橼酸氯米芬治疗低生育力PCOS女性效果更好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b5e11229961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340409, encodeId=365b13404093f, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期, objectType=article, longId=82539, objectId=ade982539bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ade982539bd, replyNumber=0, likeNumber=68, createdTime=2016-11-18, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ade982539bd, moduleTitle=NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ade982539bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340408, encodeId=e68e134040894, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, objectType=article, longId=79630, objectId=1d17e9630e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d17e9630e6, replyNumber=0, likeNumber=38, createdTime=2016-10-11, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d17e9630e6, moduleTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d17e9630e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340407, encodeId=5f69134040e90, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期, objectType=article, longId=79604, objectId=a2e5e960448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e5e960448, replyNumber=0, likeNumber=85, createdTime=2016-10-10, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e5e960448, moduleTitle=NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2e5e960448)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340406, encodeId=9eb313404066d, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=JCO：治疗依从性对无病生存率的影响(乳腺国际组他莫昔芬和来曲唑1-98试验), objectType=article, longId=73340, objectId=12b6e3340ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12b6e3340ef, replyNumber=0, likeNumber=61, createdTime=2016-07-22, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12b6e3340ef, moduleTitle=JCO：治疗依从性对无病生存率的影响(乳腺国际组他莫昔芬和来曲唑1-98试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12b6e3340ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340405, encodeId=b14c1340405f0, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=Drug Des Devel Ther：来曲唑结合促性腺激素适合克罗米芬(CC)抵抗的多囊卵巢生育障碍患者, objectType=article, longId=60618, objectId=8dd46061824, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd46061824, replyNumber=0, likeNumber=72, createdTime=2015-12-16, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd46061824, moduleTitle=Drug Des Devel Ther：来曲唑结合促性腺激素适合克罗米芬(CC)抵抗的多囊卵巢生育障碍患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dd46061824)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340404, encodeId=9a8a1340404ce, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=NEJM：来曲唑、促性腺激素、或克罗米芬治疗原因不明的不孕不育, objectType=article, longId=56548, objectId=fecf565489f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fecf565489f, replyNumber=0, likeNumber=100, createdTime=2015-09-26, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fecf565489f, moduleTitle=NEJM：来曲唑、促性腺激素、或克罗米芬治疗原因不明的不孕不育, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fecf565489f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340403, encodeId=3bf7134040389, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究, objectType=article, longId=56019, objectId=a3645601997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3645601997, replyNumber=0, likeNumber=85, createdTime=2015-09-11, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3645601997, moduleTitle=招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3645601997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340402, encodeId=59d41340402d8, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=JCO：不同亚型乳腺癌，使用来曲唑效果不同, objectType=article, longId=54176, objectId=4fd1541e61c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fd1541e61c, replyNumber=0, likeNumber=131, createdTime=2015-07-31, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fd1541e61c, moduleTitle=JCO：不同亚型乳腺癌，使用来曲唑效果不同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fd1541e61c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340401, encodeId=3021134040165, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=NEJM：来曲唑更能提高多囊卵巢综合症患者的生育能力, objectType=article, longId=38015, objectId=d312380152c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d312380152c, replyNumber=0, likeNumber=0, createdTime=2014-07-20, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d312380152c, moduleTitle=NEJM：来曲唑更能提高多囊卵巢综合症患者的生育能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d312380152c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1340400, encodeId=020c134040001, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a>, objectTitle=JCO：来曲唑联合buparlisib治疗乳腺癌安全可靠, objectType=article, longId=33711, objectId=ee1e33e11fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee1e33e11fe, replyNumber=0, likeNumber=134, createdTime=2014-04-24, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee1e33e11fe, moduleTitle=JCO：来曲唑联合buparlisib治疗乳腺癌安全可靠, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee1e33e11fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

来曲唑

2020-05-29

heli0118 (审核中...)

前往app查看评论内容

#来曲唑#

Breast Cancer Res Treat：Palbociclib加来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的一线治疗效果

2020-06-16

heli0118 (审核中...)

前往app查看评论内容

#来曲唑#

恒瑞医药来曲唑片通过仿制药一致性评价

2019-11-09

heli0118 (审核中...)

前往app查看评论内容

#来曲唑#

仑伐替尼联合来曲唑在绝经后HR+局部晚期/转移性乳腺癌中的探索

2019-05-28

heli0118 (审核中...)

前往app查看评论内容

#来曲唑#

Lancet oncol：来曲唑维持治疗不能延长乳腺癌患者化疗后的无病存活期

2018-12-10

heli0118 (审核中...)

前往app查看评论内容

#来曲唑#

J Clin Oncol：来曲唑治疗延长至10年乳腺癌症的患者生活质量有无影响？

2018-04-01

heli0118 (审核中...)

前往app查看评论内容

#来曲唑#

重复 Lancet Oncol：绝经后乳腺癌患者：延长来曲唑的间歇使用能否改善无疾病存活率？

2017-12-28

heli0118 (审核中...)

前往app查看评论内容

#来曲唑#

Lancet Oncol：来曲唑治疗方案对早期乳腺癌患者无进展生存期的影响

2017-11-22

heli0118 (审核中...)

前往app查看评论内容

#来曲唑#

Hum Reprod：来曲唑比枸橼酸氯米芬治疗低生育力PCOS女性效果更好

2017-09-09

siiner (审核中...)

前往app查看评论内容

#来曲唑#

NEJM：Palbociclib+来曲唑治疗可显著延长晚期乳腺癌患者的无进展生存期

2016-11-18

siiner (审核中...)

前往app查看评论内容

#来曲唑#

ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）

2016-10-11

siiner (审核中...)

前往app查看评论内容

#来曲唑#

NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期

2016-10-10

siiner (审核中...)

前往app查看评论内容

#来曲唑#

JCO：治疗依从性对无病生存率的影响(乳腺国际组他莫昔芬和来曲唑1-98试验)

2016-07-22

siiner (审核中...)

前往app查看评论内容

#来曲唑#

Drug Des Devel Ther：来曲唑结合促性腺激素适合克罗米芬(CC)抵抗的多囊卵巢生育障碍患者

2015-12-16

siiner (审核中...)

前往app查看评论内容

#来曲唑#

NEJM：来曲唑、促性腺激素、或克罗米芬治疗原因不明的不孕不育

2015-09-26

siiner (审核中...)

前往app查看评论内容

#来曲唑#

招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究

2015-09-11

siiner (审核中...)

前往app查看评论内容

#来曲唑#

JCO：不同亚型乳腺癌，使用来曲唑效果不同

2015-07-31

siiner (审核中...)

前往app查看评论内容

#来曲唑#

NEJM：来曲唑更能提高多囊卵巢综合症患者的生育能力

2014-07-20

siiner (审核中...)

前往app查看评论内容

#来曲唑#

JCO：来曲唑联合buparlisib治疗乳腺癌安全可靠

2014-04-24

科室
- - 订阅+
  - 更多科室
工具
服务